Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
News Brief: Long-Acting Forms of First- and Second-Generation Antipsychotics Go Head to Head

May 20, 2014. Recent clinical trials such as CATIE have raised doubts about the advantages of oral forms of second-generation antipsychotics over their earlier counterparts (see SRF related news report; SRF news report). Making the same comparison between the long-acting injectable forms of these drugs, developed to increase medication adherence, has been difficult because injectable forms of atypical antipsychotics have only been available for the last decade. The first randomized clinical trial comparing long-acting injectable forms of first- and second-generation antipsychotics, published May 20 in JAMA and led by T. Scott Stroup, Columbia University, New York, reports differences in side effect profiles, but not efficacy.

In the ACLAIMS (A Comparison of Long-Acting Medications for Schizophrenia) trial, first author Joseph McEvoy, Georgia Regents University, Augusta, and colleagues compared first-generation haloperidol decanoate to the newer paliperidone palmitate in 311 adults with schizophrenia or schizoaffective disorder judged to be at risk for relapse. Paliperidone is a metabolite of risperidone, and the injectable form is sold by Janssen Pharmaceutica under the trade names INVEGA SUSTENNA in the United States and Xeplion in countries in Europe and elsewhere.

Over a period of up to two years, the two drugs were nearly identical in terms of efficacy failure rates. Approximately one-third of patients in both groups were reported to have a psychiatric hospitalization, an increase in outpatient visits, or other clinical intervention. By contrast, side effect profiles between the two injectables did differ: Paliperidone palmitate was associated with more weight gain and higher serum prolactin levels, while haloperidol decanoate was associated with more akathisia, or inner restlessness.

In an editorial accompanying the article, Donald Goff, New York University, writes, "Setting aside the substantial differences in cost between haloperidol decanoate and paliperidone palmitate, the results from the ACLAIMS trial suggest that drug selection should be based on anticipated adverse effects rather than efficacy."—Allison A. Curley.

Reference:
McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS. Effectiveness of paliperidone palmitate vs. haloperidol decanoate for maintenance treatment of schizophrenia. JAMA. 2014;311(19):1978-1986. Abstract

 
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


SRF News
SRF Comments
Text Size
Reset Text Size
Share/Bookmark
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright